ImmunoPrecise Antibodies is a biotechnology business based in the US. ImmunoPrecise Antibodies shares (IPA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.35 – a decrease of 21.62% over the previous week. ImmunoPrecise Antibodies employs 72 staff and has a trailing 12-month revenue of around $24.1 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.35 |
|---|---|
| 52-week range | $0.35 - $2.60 |
| 50-day moving average | $0.57 |
| 200-day moving average | $1.08 |
| Wall St. target price | $6.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.76 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.3859 from 2024-11-20
| 1 week (2024-11-15) | -13.18% |
|---|---|
| 1 month (2024-10-23) | -27.94% |
| 3 months (2024-08-22) | -53.78% |
| 6 months (2024-05-22) | -67.02% |
| 1 year (2023-11-22) | -70.77% |
|---|---|
| 2 years (2022-11-22) | -92.24% |
| 3 years (2021-11-22) | 5.36 |
| 5 years (2019-11-22) | 2.465 |
| Revenue TTM | $24.1 million |
|---|---|
| Gross profit TTM | $11.6 million |
| Return on assets TTM | -13.45% |
| Return on equity TTM | -64.04% |
| Profit margin | -115.22% |
| Book value | $1.20 |
| Market Capitalization | $13.3 million |
TTM: trailing 12 months
We're not expecting ImmunoPrecise Antibodies to pay a dividend over the next 12 months.
You may also wish to consider:
ImmunoPrecise Antibodies's shares were split on a 1:5 basis on 22 November 2020 . So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your ImmunoPrecise Antibodies shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for ImmunoPrecise Antibodies shares which in turn could have impacted ImmunoPrecise Antibodies's share price.
Over the last 12 months, ImmunoPrecise Antibodies's shares have ranged in value from as little as $0.3503 up to $2.6. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ImmunoPrecise Antibodies's is 0.273. This would suggest that ImmunoPrecise Antibodies's shares are less volatile than average (for this exchange).
To put ImmunoPrecise Antibodies's beta into context you can compare it against those of similar companies.
ImmunoPrecise Antibodies Ltd. , a biotechnology company, leverages multi-omics modeling and artificial intelligence through a series proprietary and patented technologies. The company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; peptide production for subsequent antibody discovery campaign; B cell select platform, which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. In addition, it provides phage display, a custom immune library; CAR development, an adaptable antibody, which allows the inclusion of functional data early in the screening funnel; antibody sequencing; and assay development. Further, it offers a profiling toolset for antibody lead candidates; and in vitro analytical tools for the study of quality attributes.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
The best platforms to use for automatic investing include Wealthfront, SoFi, Schwab, Vanguard, Titan, Acorns and more. See our full list here.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
5 Betterment robo-advisor alternatives to consider when building your portfolio.
What you need to know about investing in the leading indicator for the overall US stock market.
How do you gift stocks to loved ones? Learn the ins and outs of finding the right investments for them.
Check out the best-performing ETFs so far in 2024.
Acorns is a financial service that rounds up your purchases and turns the extra change into investments.